Update of Gepants in the Treatment of Chronic Migraine
- 1 September 2023
- journal article
- review article
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 27 (10) , 561-569
Abstract
Purpose of Review Despite the unmet therapeutic needs of patients with chronic migraine (CM) and/or medication overuse, available treatment options are limited. Recently, four calcitonin gene-related peptide receptor antagonists, known as gepants, have been approved for the treatment of migraine. This review focuses on the preventive treatment of CM with gepants and highlights recent findings. Recent Findings Two randomized controlled trials (RCTs) have shown promising results for rimegepant and atogepant as preventive treatments for CM. In an RCT targeting patients with CM, atogepant demonstrated a significant reduction in the mean monthly migraine days, irrespective of acute medication overuse. Moreover, the patients reported no significant safety concerns and exhibited good tolerance to treatment. Summary These findings highlight the potential of gepants as a new and effective therapeutic option for patients with CM and/or medication overuse. Gepant use will help improve the management and quality of life of individuals with this debilitating condition.Keywords
This publication has 61 references indexed in Scilit:
- Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized StudyHeadache: The Journal of Head and Face Pain, 2011
- Long‐Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized TrialHeadache: The Journal of Head and Face Pain, 2010
- Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists in the Treatment of MigraineCNS Drugs, 2010
- Randomized, controlled trial of telcagepant for the acute treatment of migraineNeurology, 2009
- Global prevalence of chronic migraine: A systematic reviewCephalalgia, 2009
- Prevalence of chronic migraine and medication overuse headache in Germany—the German DMKG headache studyCephalalgia, 2009
- Tracing transformationNeurology, 2009
- Modifiable Risk Factors for Migraine ProgressionHeadache: The Journal of Head and Face Pain, 2006
- Medication-overuse headache: a worldwide problemThe Lancet Neurology, 2004
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990